S. Karger AG

SHERPA: Unknown

People

  1. Lesokhin
    Lesokhin
  2. Hultcrantz
    Hultcrantz

Groups

  1. Center for Hematologic Malignancies (5)
  2. Department of Medicine (5)
  3. Hematologic Malignancies, Division of (5)
  4. Myeloma (5)
  5. Hematologic Malignancies Research (3)
  6. Sloan Kettering Institute Postdocs (2)
Search Within
  1. "Myeloma"
Formats
  1. Meeting Abstract (5)
Groups
  1. Center for Hematologic Malignancies (5)
  2. Department of Medicine (5)
  3. Hematologic Malignancies, Division of (5)
  4. Myeloma (5)
  5. Hematologic Malignancies Research (3)
  6. Sloan Kettering Institute Postdocs (2)
People
  1. Alexander Lesokhin (3)
  2. Malin Hultcrantz (2)
Years
  1. 2023 (3)
  2. 2022 (1)
  3. 2020 (1)
Publications
  1. Oncology Research and Treatment (5)

Results (5)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of elranatamab in pts with relapsed/ refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies
    Meeting Abstract

    Raab, M. S.; Hanel, M.; Nooka, A. K.; Lesokhin, A. M.; Mohty, M.; Niesvizky, R.; Maisel, C.; Arnulf, B.; Larson, S. M.; Varshavsky-Yanovsky, A. N.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): extended follow up and biweekly administration from the MagnetisMM-3 study
    Meeting Abstract

    Raab, M. S.; Hänel, M.; Mohty, M.; Tomasson, M. H.; Arnulf, B.; Bahlis, N. J.; Prince, H. M.; Niesvizky, R.; Rodríguez-Otero, P.; Martinez-Lopez, J.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple myeloma (RRMM): a subgroup analysis from MagnetisMM-3
    Meeting Abstract

    Raab, M. S.; Hänel, M.; Raje, N.; Leleu, X.; Lesokhin, A.; Mohty, M.; Nooka, A. K.; Leip, E.; Conte, U.; Viqueira, A.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma (RRMM): DREAMM-14
    Meeting Abstract

    Salwender, H.; Hultcrantz, M.; Kleinman, D.; Ghataorhe, P.; McKeown, A.; He, W.; Ling, T.; Jewell, R.; Byrne, J.; Eliason, L.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment
    Meeting Abstract

    Kortüm, M.; Lee, H. C.; Cohen, A. D.; Chari, A.; Hultcrantz, M.; Nooka, A. K.; Callander, N.; Suvannasankha, A.; Badros, A.; Libby, E.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save